Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Tuesday.

Separately, Zacks Investment Research lowered Eleven Biotherapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 24th.

Eleven Biotherapeutics (NASDAQ:EBIO) traded up 0.775% on Tuesday, reaching $1.431. The company’s stock had a trading volume of 198,238 shares. The company has a market capitalization of $22.03 million, a price-to-earnings ratio of 9.477 and a beta of 3.38. The firm’s 50 day moving average price is $1.62 and its 200-day moving average price is $1.97. Eleven Biotherapeutics has a 52 week low of $1.31 and a 52 week high of $5.97.

Eleven Biotherapeutics (NASDAQ:EBIO) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter. The company had revenue of $0.43 million for the quarter. Eleven Biotherapeutics had a return on equity of 7.73% and a net margin of 11.28%. On average, equities analysts predict that Eleven Biotherapeutics will post ($1.75) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/06/13/eleven-biotherapeutics-inc-ebio-lowered-to-strong-sell-at-valuengine.html.

Several large investors have recently modified their holdings of EBIO. Geode Capital Management LLC increased its stake in shares of Eleven Biotherapeutics by 0.6% in the first quarter. Geode Capital Management LLC now owns 47,187 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 300 shares in the last quarter. Oxford Asset Management purchased a new stake in Eleven Biotherapeutics during the fourth quarter worth $343,000. Finally, Vanguard Group Inc. increased its stake in Eleven Biotherapeutics by 45.1% in the first quarter. Vanguard Group Inc. now owns 175,850 shares of the biopharmaceutical company’s stock worth $386,000 after buying an additional 54,694 shares during the period. 9.72% of the stock is currently owned by institutional investors.

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.